| [1] Santini V,Kantarjian HM,Issa JP. Changes in DNA methylation in neoplasia:Pathophysiology and therapeutic implications[J].Ann Intern Med,2001,134(7):573-586.[2] Egger G,Liang GN,Aparicio A,et al.Epigenetics in human disease and prospects for epigenetic therapy[J].Nature,2004,429(6990):457-463.[3] Herman J,Baylin SB.Mechanisms of disease:Gene silencing in cancer in association with promoter hypermethylation[J].New Engl J Med,2003,349(21):2042-2054.[4] 段善州,陈勇兵,杨文涛,等.地西他滨对肺腺癌细胞生长的影响[J].江苏医药,2013(03):260-262.[5] Liu QY,Chen DW,Xie LP,et al.Decitabine,independent of apoptosis,exerts its cytotoxic effects on cell growth in melanoma cells[J].Environ Toxicol Phar,2011,32(3):423-429.[6] Al-Romaih K,Sadikovic B,Yoshimoto M,et al.Decitabine-induced demethylation of 5'CpG island in GADD45A leads to apoptosis in osteosarcoma cells[J].Neoplasia,2008,10(5):471-480.[7] Shin DY,Kim GY,Kim CG,et al.Anti-invasive effects of decitabine,a DNA methyltransferase inhibitor,through tightening of tight junctions and inhibition of matrix metalloproteinase activities in AGS human gastric carcinoma cells[J].Oncol Rep,2012,28(3):1043-1050.[8] Cowan LA,Talwar S,Yang AS.Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors[J]. Epigenomics,2010,2(1):71-86.[9] Appleton K,Mackay HJ,Judson I,et al.Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors[J].J Clin Oncol,2007,25(29):4603-4609.[10] Fang F,Balch C,Schilder J,et al.A Phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent,platinum-resistant,epithelial ovarian cancer [J].Cancer,2010,116(17):4043-4053.[11] Matei D,Fang F,Shen C,et al.Epigenetic resensitization to platinum in ovarian cancer [J].Cancer Res,2012,72(9):2197-2205.[12] Pohlmann P,DiLeone LP,Cancella AI,et al.Phase Ⅱ trial of cisplatin plus decitabine,a new DNA hypomethylating agent,in patients with advanced squamous cell carcinoma of the cervix [J].Am J Clin Oncol,2002,25(5):496-501.[13] Schwartsmann G,Schunemann H,Gorini CN,et al.A phase Ⅰ trial of cisplatin plus decitabine,a new DNA-hypomethylating agent,in patients with advanced solid tumors and a follow-up early phase Ⅱ evaluation in patients with inoperable non-small cell lung cancer[J].Invest New Drug,2000,18(1):83-91.[14] George RE,Laht JM,Adamson PC,et al.Phase Ⅰ Study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors:A Children's Oncology Group Study[J].Pediatr Blood Cancer,2010,55(4):629-638.[15] Tawbi HA,Beumer JH,Tarhini AA,et al.Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma:a phase Ⅰ/Ⅱ study and pharmacokinetic analysis[J].Ann Oncol,2013,24(4):1112-1119.[16] Fraga MF,Ballestar E,Villar-Garea A,et al.Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer[J].Nat Genet,2005,37(4):391-400.[17] Weichert W,Röske A,Gekeler V,et al.Association of patterns of class Ⅰ histone deacetylase expression with patient prognosis in gastric cancer:a retrospective analysis[J].Lancet Oncol,2008,9(2):139-148.[18] Hanmod SS,Wang G,Edwards H,et al.Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma[J].Pediatr Blood Cancer,2015,62(1):52-59.[19] Kastl L,Brown I,Schofield AC.1018 Trichostatin A and decitabine reverses resistance to docetaxel in human breast cancer cells [J].Eur J Cancer Suppl,2009,7(2):92.[20] Yang DF,Torres CM,Bardhan K,et al.Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to fas ligand-induced apoptosis in vitro and tumor suppression in vivo[J].J Immunol,2012,188(9):4441-4449.[21] Stathis A,Hotte SJ,Chen EX,et al.Phase Ⅰ study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-hodgkin's Lymphomas[J].Clin Cancer Res,2011,17(6):1582-1590.[22] 张国强,彭敏霞,王晔恺,等,地西他滨联合丙戊酸钠促进胃癌MGC-803细胞凋亡和G0/G1期阻滞的机制研究[J].中国病理生理杂志,2012,28(10):1856-1860.[23] Ecke I,Petry F,Rosenberger A,et al.Antitumor effects of a combined 5-Aza-2' deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in ptch mutant mice[J].Cancer Res,2009,69(3):887-895.[24] Chu BF,Karpenko MJ,Liu Z,et al.Phase Ⅰ study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer[J].Cancer Chemoth Pharm,2013,71(1):115-121.[25] Aparicio A,North B,Barske L,et al.LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors[J].Epigenetics,2009,4(3):176-184.[26] Coral S,Sigalotti L, Altomonte M,et al.5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma:Immunotherapeutic implications[J].Clin Cancer Res,2002,8(8):2690-2695.[27] Karpf AR,Lasek AW,Ririe TO,et al.Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine[J].Mol Pharmacol,2004,65(1):18-27.[28] De Smet C,De Backer O,Faraoni I,et al.The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation[J].Proc Natl Acad Sci U S A,1996,93(14):7149-7153.[29] Gollob JA,Sciambi CJ,Peterson BL,et al.Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma[J].Clin Cancer Res,2006,12(15):4619-4627.[30] Garrido-Laguna I,McGregor KA,Wade M,et al.A phase Ⅰ/Ⅱ study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer[J].Invest New Drug,2013,31(5):1257-1264. |
